New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin

被引：33

作者：

Bates, SM

Weitz, JI

机构：

[1] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada

[2] McMaster Univ, Dept Med, Hamilton, ON, Canada

[3] McMaster Univ, Dept Biochem, Hamilton, ON, Canada

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2005年 / 144卷 / 08期

关键词：

anticoagulant; antithrombotic; venous thromboembolism; arterial thromboembolism; direct thrombin inhibitor; pentasaccharide;

D O I：

10.1038/sj.bjp.0706153

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing.

引用

页码：1017 / 1028

页数：12

共 134 条

[1] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].

Abraham, E ;

Reinhart, K ;

Svoboda, P ;

Seibert, A ;

Olthoff, D ;

Dal Nogare, A ;

Postier, R ;

Hempelmann, G ;

Butler, T ;

Martin, E ;

Zwingelstein, C ;

Percell, S ;

Shu, V ;

Leighton, A ;

Creasey, AA .

CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089

[2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].

Abraham, E ;

Reinhart, K ;

Opal, S ;

Demeyer, I ;

Doig, C ;

Rodriguez, AL ;

Beale, R ;

Svoboda, P ;

Laterre, PF ;

Simon, S ;

Light, B ;

Spapen, H ;

Stone, J ;

Seibert, A ;

Peckelsen, C ;

De Deyne, C ;

Postier, R ;

Pettilä, V ;

Sprung, CL ;

Artigas, A ;

Percell, SR ;

Shu, V ;

Zwingelstein, C ;

Tobias, J ;

Poole, L ;

Stolzenbach, JC ;

Creasey, AA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247

[3]

AGNELLI G, 2003, J THROMB HAEMOST S, V1

[4]

Albers GW, 2003, LANCET, V362, P1691

[5] Antithrombotic therapy in atrial fibrillation [J].

Albers, GW ;

Dalen, JE ;

Laupacis, A ;

Manning, WJ ;

Petersen, P ;

Singer, DE .

CHEST, 2001, 119 (01) :194S-206S

[6] Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot [J].

Alexander, JH ;

Dyke, CK ;

Yang, H ;

Becker, RC ;

Hasselblad, V ;

Zillman, LA ;

Kleiman, NS ;

Hochman, JS ;

Berger, PB ;

Cohen, EA ;

Lincoff, AM ;

Saint-Jacques, H ;

Chetcuti, S ;

Burton, JR ;

Buergler, JM ;

Spence, FP ;

Shimoto, Y ;

Robertson, TL ;

Kunitada, S ;

Bovill, EG ;

Armstrong, PW ;

Harrington, RA .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (02) :234-241

[7] Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia [J].

Amiral, J ;

Lormeau, JC ;

MarfaingKoka, A ;

Vissac, AM ;

Wolf, M ;

BoyerNeumann, C ;

Tardy, B ;

Herbert, JM ;

Meyer, D .

BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (02) :114-117

[8]

AOKI Y, 1994, THROMB HAEMOSTASIS, V71, P452

[9] Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa [J].

Arnljots, B ;

Ezban, M ;

Hedner, U .

JOURNAL OF VASCULAR SURGERY, 1997, 25 (02) :341-346

[10]

Bajaj MS, 1997, THROMB HAEMOSTASIS, V78, P471

← 1 2 3 4 5 6 7 8 9 10 →